Page 4 - Serum Institute Of India

Confusion, fear behind reluctance to take Covid booster, says experts

According to virologist Dr T Jacob John, vaccine fatigue has set in, also because the "cacophony of new experts" has been confusing

SII urges Centre to use free 100 mn Covishield doses by GAVI as cases rise

The Serum Institute of India has urged the Centre to use the available 10 crore doses of Covishield offered free of cost under COVAX facility in view of rising Covid cases, an official source said.

Serum Institute halts Covid-19 vaccine production amid global supply glut

Serum has cited protectionist measures in other countries that led to a shortage of raw materials as one reason it fell short of vaccine production goals at the height of the pandemic

Top headlines: Govt preps Pawan Hans sale, Serum faces Covid vaccine glut

The government will finalise the sale of state-owned helicopter service provider Pawan Hans this week. More on that story in our top headlines this hour.

Serum CEO Poonawalla warns against return to business-as-usual approach

He pointed out that there is rising vaccine fatigue among the public as the main reason for the low off-take of the vaccines

Delhi govt makes Covid precautionary dose free for beneficiaries aged 18-59

All those who are over 18 years of age and have completed nine months after the administration of the second dose are eligible for the precaution dose

Reduce time gap for Covid vaccine booster dose to 6 months: SII to govt

SII CEO Adar Poonawalla stated that all across the world, the gap between second dose and booster shot is six month or less

SII to give free Covishield vials to pvt vaccination centres: Here's why

Vaccine majors SII and Bharat Biotech said they have decided to cut prices of precaution dose of their respective Covid-19 vaccines to Rs 225 per shot for private hospitals after discussion with govt

SII, Bharat Biotech cut Covid vaccine prices for pvt hospitals to Rs 225

SII and Bharat Biotech have been major suppliers of Covid-19 vaccines to the government so far

Don't slack off

Vaccination programme cannot lose govt attention

Low number of Covid cases now as India chose right vaccine: Serum CEO

In India, experts are deciding on mixing vaccines though it is allowed the world over, Poonawalla added

From Coca-Cola to Apple Inc, here are India's best unlisted companies

In all, 18 out of the best 30 unlisted companies in the 2021 league table are local subsidiaries of global multinationals.

NTAGI group to review SII's Covovax data for use in 12 yrs and above

A Covid working group of NTAGI will review this week data of SII anti-coronavirus jab Covovax to decide whether it can be included vaccination programme for inoculating those aged 12 years and above

Serum Institute seeks emergency use authorisation for its tuberculosis vax

The Serum Institute has applied to the Drugs Controller General of India seeking emergency use authorisation for its recombinant BCG (rBCG) vaccine for the prevention of tuberculosis

Second Covishield dose can be given between 8-16 weeks: NTAGI

NTAGI has recommended administering the second dose of COVID-19 vaccine Covishield between eight and 16 weeks after the first dose, official sources said on Sunday

SII seeks inclusion of Covovax in Govt vax drive for 12 yr and above

Registrations for 12-14 year olds on Co-Win will begin from Wednesday

Top Headlines: ex-NSE CEO Chitra arrested; SII bets on non-Covid vaccines

Business Standard brings you the top headlines at this hour.

Malaria to pneumonia vaccines: SII now betting on non-Covid shots

SII has the capacity to produce 250 million monthly doses of Covishield

SII seeks nod for phase-3 of Covid vax Covovax as booster in adults

Serum Institute of India has sought permission from India's drug regulator to conduct a phase-3 study of its COVID-19 vaccine Covovax as a booster dose in adults, official sources said on Sunday.

Serum Institute seeks EUA for its Covovax vaccine for 12-17 yrs age group

Serum Institute of India has sought emergency use authorisation from India's drug regulator for its Covid-19 vaccine Covovax for the 12 to 17 year age group